AllakosALLK
ALLK
About: Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
Employees: 131
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
3,000% more call options, than puts
Call options by funds: $31K | Put options by funds: $1K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
11.7% less ownership
Funds ownership: 90.77% [Q2] → 79.07% (-11.7%) [Q3]
23% less funds holding
Funds holding: 101 [Q2] → 78 (-23) [Q3]
43% less capital invested
Capital invested by funds: $80.3M [Q2] → $45.9M (-$34.5M) [Q3]
50% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 26
71% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 31
Research analyst outlook
We haven’t received any recent analyst ratings for ALLK.
Financial journalist opinion
Neutral
PRNewsWire
1 month ago
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm
NEW YORK , Dec. 19, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Allakos Inc. (NASDAQ: ALLK) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Positive
Zacks Investment Research
2 months ago
All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy
Allakos (ALLK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Seeking Alpha
2 months ago
Allakos Runs Up Into A Near-Term Catalyst
Allakos shifted focus to AK006 in 2024 after lirentelimab's failure in phase 2 trials for atopic dermatitis and chronic spontaneous urticaria. Phase 1 work with intravenous and subcutaneous AK006 demonstrates that the drug may not require frequent dosing, which may be important given potential competition from oral remibrutinib. Upcoming Q1'25 data from a randomized, double-blind, placebo-controlled trial of IV AK006 in over 30 CSU patients is a near-term catalyst.
Neutral
GlobeNewsWire
2 months ago
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2024.
Neutral
GlobeNewsWire
3 months ago
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with a favorable safety profile –– Top-line Phase 1 results of Intravenous AK006 in patients with CSU are expected in early Q1 of 2025 –
Neutral
GlobeNewsWire
5 months ago
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2024.
Neutral
Accesswire
6 months ago
The Schall Law Firm Begins Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate
LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
6 months ago
The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Engage
LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
GlobeNewsWire
6 months ago
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects treated with AK006 show high receptor occupancy –– AK006 was well-tolerated with a favorable safety profile –
Neutral
Accesswire
6 months ago
The Schall Law Firm Begins Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate
LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Charts implemented using Lightweight Charts™